Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

NCT07479732 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Osteosarcoma
Osteosarcoma Metastatic

Interventions

DRUG: Liposomal Irinotecan
DRUG: Apatinib in arm1

Sponsor

Peking University People's Hospital